O'Reilly RA, Aggeler PM, Hoag MS, et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs: the first reported kindred. N Engl J Med.1964;271:809-815.
3.
O'Reilly RAThe second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med.1970;282:1448-1454.
4.
Freeman BD, Zehnbauer BA, McGrath S., Borecki I., Buchman TGCytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery. 2000;128:281-285.
5.
Meyer UAPharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667-1671.
6.
Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541.
7.
Li T., Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541-544.
8.
D'Andrea G., D'Ambrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645-649.
9.
Margaglione M., Colaizzo D., D'Andrea G., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost.2000;84:775-778.
10.
D'Andrea G. , D'Ambrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645-649.
